| Protocol ID |
|
Title |
|
| SWOG 1117 |
|
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Keywords: Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
|
| ECOG 1411 |
|
Intergroup Randomized Phase II Four Arm Study In Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB - R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RB- LR)
Keywords: Previously Untreated Mantle Cell Lymphoma |
|
| Industry-C16010 |
|
A Phase 3, Randomized, double-Blind Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Site laceboversus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Keywords: Relapsed and/or Refractory Multiple Myeloma |
|
| FHCRC-2241 |
|
Sequential Autologous HCT/ Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Keywords: High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia |
|
| ECOG 3903 |
|
Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders
Keywords: Leukemia or Related Hematologic Disorders |
|
| RDCRN 6501 |
|
Longitudinal Study of Immune Mediated Disorders after Allogeneic Hemotopoietic Cell Transplantation
Keywords: Allogeneic Hemotopoietic Cell Transplantation |
|
| In-House-GVHD |
|
Acquisitions of Graft v. Host Disease Sample in Pre-Clinical Studies
Keywords: Graft v. Host Disease |
|
| In-House |
|
Laboratory Studies of Iron Metabolism in Blood Cells from Patients with Hematochromatosis
Keywords: patients with hematochromatosis |
|
In-House: Pre-Clinical
Vaccine for MM |
|
Pre-Clinical Studies on Vaccine Derived From Patient-Derived Myeloma Cells
Keywords: Multiple Myeloma |
|
| E2903 |
|
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia
Keywords: Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia |
|
| E1906 |
|
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia
Keywords: Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia |
|
| E2905 |
|
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid ®) Alone in Combination with Epoetin Alfa (Procrit ®) in Subjects with Low- or Intermediate -1 Risk MDS and Symptomatic Anemia
Keywords: Low- or Intermediate -1 Risk MDS and Symptomatic Anemia |
|
| AT7519M/0004 |
|
A Phase I/II Open-Label Multicenter Study of AT7519M Alone and in Combination with Bortezomib in Patients with Previously Treated Multiple Myeloma
Keywords: Patients with Previously Treated Multiple Myeloma |
|
| CTN 0702 |
|
A Trial of Single Autologous Transplant with or without Consolidation Therapy vs. Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Keywords: Patients with Multiple Myeloma |
|
| CTN 0901 |
|
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intesnsity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Keywords: Myelodysplastic Syndrome or Acute Myeloid Leukemia |
|
| E2906 |
|
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)
Keywords: Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years) |
|
| C05013 |
|
An Open-Label, Randomized, Phase II Study to Assess the Effectiveness of RCHOP with or without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
Keywords: Diffuse Large B-Cell Lymphoma |
|
| In-house |
|
Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Keywords: Refractory Acute Graft Versus Host Disease |
|
| E2408 |
|
A 3 Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide/ Rituximab in High Risk Follicular Lymphoma
Keywords: High Risk Follicular Lymphoma |
|
| Industry — Multiple Myeloma |
|
Phase I/II, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/ Refractory Multiple Myeloma
Keywords: Relapsed or Relapsed/ Refractory Multiple Myeloma |
|
| FH-2230.00 |
|
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation
Keywords: Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation |
|
| FH-2448.00 |
|
A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Trial
Keywords: Donor Hematopoietic Cell Transplantation |
|
| S0805 |
|
Phase II Study of Combination fo Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Keywords: Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) |
|
| S1106 |
|
A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients greater than or equal to 65 years of Age with Previously Untreated Mantle Cell Lymphoma
Keywords: Previously Untreated Mantle Cell Lymphoma |
|
| In-house Fenske-TC99 |
|
Development of 99mTechnetium scanning as a quantitative in vivo assay to predict chemotherapy drug resistance and clinical outcome in lymphoma patients.
Keywords: lymphoma |
|
| CTN 0801 |
|
A Phase II/III Randomized, Multi-center Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host-Disease
Keywords: Graft-versus-Host-Disease |
|
| RDCRN 6503 |
|
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Keywords: Bronchiolitis Obliterans Syndrome |
|
| RDCRN 6502 |
|
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation
Keywords: Cutaneous Sclerosis |
|
| ON 01910.Na |
|
A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72 hour Continuous Intravenous Infusion Every Other Week In Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine
Keywords: Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After or Refractory to, or Intolerant to Azacitadine or Decitabine |
|
| Industry — Acute Myeloid Leukemia |
|
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Keywords: Newly Diagnosed Acute Myeloid Leukemia, Elderly Patients |
|
| WON HO10407 |
|
A Phase II Study of Bortezomib and Temsirolimus for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Keywords: Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
|
| Industry — CLL 0115 |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Keywords: Previously Treated Chronic Lymphocytic Leukemia |
|
| Industry — CLL 0116 |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Keywords: Previously Treated Chronic Lymphocytic Leukemia |
|
| Industry — CLL 0117 |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Keywords: Previously Treated Chronic Lymphocytic Leukemia |
|
| Industry — MDS or AML |
|
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-Label, Part 2: Randomized, Double-Blind, Part 3: extension)
Keywords: Thrombocytopenic with Myelodysplastic Syndromes or Acute Myeloid Leukemia |
|
| Industry — polycythemia vera |
|
Polycythemia Vera Symptom Trial Evaluating Ruxolitinib versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes (the RELIEF study)
Keywords: Polycythemia Vera |
|
| Industry — Transplant, MM |
|
Ligand: A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCl for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Keywords: Multiple Myeloma Patients Undergoing Autologous Transplantation |
|
| Industry — Myeloproliferative Neoplasms |
|
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
Keywords: Myeloproliferative Neoplasms |
|
| Industry — Amyloidosis |
|
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Keywords: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis |
|
| University of Michigan — AML |
|
Multi-center single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen
Keywords: Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) |
|
| Industry — AML |
|
Celator CLTR0310-301: Celator 301: Phase III, Multicenter, Randomized, Trial Of CPX-351(cytarabine:daunorubicin) Liposome Injection Versus Cytarabine And Daunorubicin In Patients 60-75 Years Of Age With Untreated High Risk (Secondary) AML
Keywords: Untreated High Risk (Secondary) AML |